Proteomics in Multiple Sclerosis: The Perspective of the Clinician

Sandi, Dániel; Kokas, Zsófia; Biernacki, Tamás; Bencsik, Krisztina; Klivényi, Péter; Vécsei, László

doi:10.3390/ijms23095162

Cited by 20 publications

(17 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disease of the central nervous system in which the protective myelinated axons of the nerve fibers in the brain and spinal cord are targeted, along with parallel disruption of the blood–brain barrier. MS can be present in several forms such as a progressive or a fluctuating, relapsing-remitting type [ 103 , 104 , 105 ].…”

Section: Therapeutic Applications Of the Msc-secretome For Autoimmune...mentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases

Műzes

Sípos

2022

Cells

View full text Add to dashboard Cite

Immune-mediated inflammatory diseases (IMIDs) encompass several entities such as “classic” autoimmune disorders or immune-mediated diseases with autoinflammatory characteristics. Adult stem cells including mesenchymal stem cells (MSCs) are by far the most commonly used type in clinical practice. However, due to the possible side effects of MSC-based treatments, there is an increase in interest in the MSC-secretome (containing large extracellular vesicles, microvesicles, and exosomes) as an alternative therapeutic option in IMIDs. A wide spectrum of MSC-secretome-related biological activities has been proven thus far including anti-inflammatory, anti-apoptotic, and immunomodulatory properties. In comparison with MSCs, the secretome is less immunogenic but exerts similar biological actions, so it can be considered as an ideal cell-free therapeutic alternative. Additionally, since the composition of the MSC-secretome can be engineered, for a future perspective, it could also be viewed as part of a potential delivery system within nanomedicine, allowing us to specifically target dysfunctional cells or tissues. Although many encouraging results from pre-clinical studies have recently been obtained that strongly support the application of the MSC-secretome in IMIDs, human studies with MSC-secretome administration are still in their infancy. This article reviews the immunomodulatory effects of the MSC-secretome in IMIDs and provides insight into the interpretation of its beneficial biological actions.

show abstract

Section: Therapeutic Applications Of the Msc-secretome For Autoimmune...mentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases

Műzes

Sípos

2022

Cells

View full text Add to dashboard Cite

show abstract

“…Only about 15% of patients exhibit the primary progressive (PPMS) form of the disease at the onset, featured by the progressive accumulation of neurological damage. Thus, there are three major clinical forms of MS: RRMS, SPMS, and PPMS [ 1 , 6 , 8 ].…”

Section: Multiple Sclerosismentioning

confidence: 99%

Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways

et al. 2022

View full text Add to dashboard Cite

Multiple sclerosis (MS) encompasses a chronic, irreversible, and predominantly immune-mediated disease of the central nervous system that leads to axonal degeneration, neuronal death, and several neurological symptoms. Although various immune therapies have reduced relapse rates and the severity of symptoms in relapsing-remitting MS, there is still no cure for this devastating disease. In this brief review, we discuss the role of mitochondria dysfunction in the progression of MS, focused on the possible role of Nrf2 signaling in orchestrating the impairment of critical cellular and molecular aspects such as reactive oxygen species (ROS) management, under neuroinflammation and neurodegeneration in MS. In this scenario, we propose a new potential downstream signaling of Nrf2 pathway, namely the opening of hemichannels and pannexons. These large-pore channels are known to modulate glial/neuronal function and ROS production as they are permeable to extracellular Ca2+ and release potentially harmful transmitters to the synaptic cleft. In this way, the Nrf2 dysfunction impairs not only the bioenergetics and metabolic properties of glial cells but also the proper antioxidant defense and energy supply that they provide to neurons.

show abstract

“…Like AD and PD, MS can be categorized into neurodegenerative disorders in the CNS; however, it has distinct features of progressive immune-mediated neuro-inflammatory evens resulting in multiple demyelinating lesions ( Yamasaki and Kira 2019 ). Although tremendous efforts have been made on the achievement of myelin repair and neuroprotection in MS, its complex pathogenesis obstacles satisfactory outcomes for the patients with progressive phase ( Sandi et al, 2022 ).…”

Section: Potential Efficacy Of Glp-1ras Toward Demyelinating Disordersmentioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Sango

Takaku

Tsukamoto

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were developed as insulinotropic and anti-hyperglycemic agents for the treatment of type 2 diabetes, but their neurotrophic and neuroprotective activities have been receiving increasing attention. Myelin plays a key role in the functional maintenance of the central and peripheral nervous systems, and recent in vivo and in vitro studies have shed light on the beneficial effects of GLP-1RAs on the formation and protection of myelin. In this article, we describe the potential efficacy of GLP-1RAs for the induction of axonal regeneration and remyelination following nerve lesions and the prevention and alleviation of demyelinating disorders, particularly multiple sclerosis.

show abstract

Proteomics in Multiple Sclerosis: The Perspective of the Clinician

Cited by 20 publications

References 208 publications

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases

Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Contact Info

Product

Resources

About